In a landmark regulatory achievement that reflects the UAE’s leadership in accelerating access to innovative therapies, the Emirates Drug Establishment has announced the approval of “Tolebrutinib” as the world’s first oral treatment for non-relapsing secondary progressive multiple sclerosis (SPMS). The approval was based on a scientific study conducted in collaboration with the National Multiple Sclerosis Society. At the Emirates Drug Establishment, we believe in fast-tracking regulatory processes in areas of high medical need. The adoption of this advanced scientific approach, coupled with effective collaboration, underscores the UAE’s leadership in accelerating access to scientific innovation. It also reflects the Emirates Drug Establishment’s genuine commitment to improving patients’ outcomes and expanding access to evidence-based care.